/

Empresas

Da

No verificado

Daiichi Sankyo

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

108 Comunicados de prensa

Ver todos los comunicados de prensa

18/09/2026

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Industria

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer

Fuente

Editor

1.00

0

14/09/2026

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Eventos

Industria

Enhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial

Fuente

Editor

1.00

0

01/09/2026

Industria

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Oncología

Enhertu® Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer

Fuente

Editor

1.00

0

28/08/2026

Eventos

Industria

Salud

Medicina - Varios

Ciencia

Farmacéutica

Cardiología

Biotecnología

Nuovi dati di Daiichi Sankyo evidenziano l'effetto dell'acido bempedoico nella gestione della dislipidemia e del rischio cardiovascolare nella pratica clinica

Fuente

Editor

1.00

0

28/08/2026

Eventos

Industria

Salud

Medicina - Varios

Ciencia

Farmacéutica

Cardiología

Biotecnología

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk

Fuente

Editor

1.00

0

27/08/2026

Oncología

Salud

Medicina - Varios

Sanidad

Farmacéutica

Biotecnología

DS1025 Enters Clinical Development in Patients with Advanced Solid Tumors as Novel CD25 Directed ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo

Fuente

Editor

1.00

0

26/08/2026

Industria

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Oncología

TROPION-Urothelial04 Phase 3 Trial of Datroway® Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer

Fuente

Editor

1.00

0

24/08/2026

Mercado laboral

Material médico sanitario

Salud

Sanidad

Farmacéutica

Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization

Fuente

Editor

1.00

0

24/08/2026

Mercado laboral

Biotecnología

Sanidad

Salud

Farmacéutica

Oncología

Daiichi Sankyo Appoints Ken Keller as Chief Commercialization Officer to Lead New Commercialization Unit to Accelerate Growth of Innovative Portfolio

Fuente

Editor

1.00

0

17/08/2026

Industria

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0